<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707692</url>
  </required_header>
  <id_info>
    <org_study_id>160089</org_study_id>
    <secondary_id>1R01AI118422-01A1</secondary_id>
    <nct_id>NCT02707692</nct_id>
  </id_info>
  <brief_title>Perturbing of HIV Reservoir With Immune Stimulation</brief_title>
  <official_title>Perturbing the HIV Reservoir With Immune Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the impact of Pneumococcus and Influenza vaccines
      on the HIV transcriptional activity in individuals who are virologically suppressed for at
      least 48 weeks on similar ART. The proposed study is a randomized double-blinded control
      trial conducted over 28 weeks. Randomized interventions will be injections of Influenza
      vaccine, Pneumococcal vaccine, and Placebo. Each participant will receive each injection but
      in a randomized order.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Perturbing the HIV Reservoir

      Sample Size: 56

      Study Population: HIV-infected individuals between 18 and 50 years old who started similar
      antiretroviral therapy (ART) during chronic infection and remained virally suppressed for at
      least 48 weeks before enrollment. Participants will have CD4 &gt;350 cells/μl at enrollment and
      a CD4 nadir &gt;200 cells/μl.

      Participating Sites: UCSD's Antiviral Research Center (AVRC)

      Study Design: The proposed study is a randomized double-blinded control trial conducted over
      28 weeks. Randomized interventions will be injections of Influenza vaccine, Pneumococcal
      vaccine, and Placebo. Each participant will receive each injection but in a randomized order.

      Schedule of Evaluations: Study evaluations will be based on three 30 day cycles (Influenza
      vaccine, Pneumococcus vaccine, Placebo in random order) over 28 weeks of the RCT. Pre
      injection: one paired blood and genital secretion sample will be collected before each
      injection. Post-injection: paired blood and genital secretion samples will be collected on
      days 2, 4, 7, 14 and 30 after each injection.

      Study Duration: 240 weeks

      Study Regimen/Intervention: This is a double blind RCT of two vaccines (Pneumovax®23 and
      Fluarix®) plus placebo (sterile saline injection). Study participants will be followed for 28
      weeks after enrollment. During this 28-week period, blood and genital secretion samples will
      be collected on day 0 and five subsequent time points after each injection (days 2, 4, 7, 14
      and 30). Injections (vaccine or placebo) will be administered 12 weeks apart and in a random
      order, to minimize a possible bias due to the order of the vaccines.

      Primary Objective: To determine the impact of Pneumococcus and Influenza vaccines on the HIV
      transcriptional activity in individuals who are virologically suppressed for at least 48
      weeks on similar ART.

      Primary Outcome: Average level of CD4+ T cell-associated HIV RNA transcription measured at
      days 2, 4, 7, 14 and 30 after each injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+ T cell-associated HIV RNA transcription</measure>
    <time_frame>Day 7</time_frame>
    <description>Average level of CD4+ T cell-associated HIV RNA transcription measured at day 7 after each injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV DNA Levels</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of HIV DNA measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (IL-6)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: soluble IL-6 using commercial validated assays (ELISA) measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (TNF)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: soluble TNF using commercial validated assays (ELISA) measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (sCD14)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: soluble CD14 using commercial validated assays (ELISA) measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (sCD163)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: soluble CD163 (sCD163) using commercial validated assays (ELISA) measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (CD3)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: cellular marker CD3 measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (CD4)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: cellular marker CD4 measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (CD8)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: cellular marker CD8 measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (CD38)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: cellular marker CD38 measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation (DR)</measure>
    <time_frame>Days 2, 4, 7, 14, 30</time_frame>
    <description>Levels of Immune Activation: cellular marker DR measured at 2, 4, 7, 14, 30 days after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selective HIV RNA Production</measure>
    <time_frame>30 days post vaccination</time_frame>
    <description>Determine selective HIV RNA production from HIV DNA (by next generation sequencing and panmixia tests) among the five participants with the highest levels of cell associated HIV RNA following active vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonselective HIV RNA Production</measure>
    <time_frame>30 days post vaccination</time_frame>
    <description>Determine nonselective HIV RNA production from HIV DNA (by next generation sequencing and panmixia tests) among the five participants with the highest levels of cell associated HIV RNA following active vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of replication competent HIV DNA</measure>
    <time_frame>30 days post vaccination</time_frame>
    <description>Levels of replication competent HIV DNA (by quantitative viral outgrowth assays) among the five participants with the highest levels of cell associated HIV RNA following active vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of HIV specific immune response</measure>
    <time_frame>30 days post vaccinations</time_frame>
    <description>Levels of HIV specific immune response 30 days after each injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulation of HIV transcription (incidental illness)</measure>
    <time_frame>30 days post vaccinations</time_frame>
    <description>Measure stimulation of HIV transcription by incidental illness over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulation of HIV transcription (human herpesvirus replication)</measure>
    <time_frame>30 days post vaccinations</time_frame>
    <description>Measure stimulation of HIV transcription by human herpesviruses replication over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulation of HIV transcription (microbial translocation)</measure>
    <time_frame>30 days post vaccinations</time_frame>
    <description>Measure stimulation of HIV transcription by microbial translocation over the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>AIDS</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Placebo, Flu, Pneumovax</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each subject will take Influenza (Fluarix®, GSK), Pneumococcal (Pneumovax®23, Merck), and placebo. Randomization will determine the order in which the subjects receive the injections. There are six potential study arms, one for each order in which someone could receive the injections:
Arm 1: Placebo, Flu, Pneumovax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo, Pneumovax, Flu</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 2: Placebo, Pneumovax, Flu</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Flu, Placebo, Pneumovax</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 3: Flu, Placebo, Pneumovax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Pneumovax, Placebo, Flu</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 4: Pneumovax, Placebo, Flu</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Pneumovax, Flu, Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 5: Pneumovax, Flu, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: Flu, Pneumovax, Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 6: Flu, Pneumovax, Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>Intramuscular injection with Fluarix® .</description>
    <arm_group_label>Placebo, Flu, Pneumovax</arm_group_label>
    <arm_group_label>Arm 2: Placebo, Pneumovax, Flu</arm_group_label>
    <arm_group_label>Arm 3: Flu, Placebo, Pneumovax</arm_group_label>
    <arm_group_label>Arm 4: Pneumovax, Placebo, Flu</arm_group_label>
    <arm_group_label>Arm 5: Pneumovax, Flu, Placebo</arm_group_label>
    <arm_group_label>Arm 6: Flu, Pneumovax, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax</intervention_name>
    <description>Intramuscular injection with Pneumovax.</description>
    <arm_group_label>Placebo, Flu, Pneumovax</arm_group_label>
    <arm_group_label>Arm 2: Placebo, Pneumovax, Flu</arm_group_label>
    <arm_group_label>Arm 3: Flu, Placebo, Pneumovax</arm_group_label>
    <arm_group_label>Arm 4: Pneumovax, Placebo, Flu</arm_group_label>
    <arm_group_label>Arm 5: Pneumovax, Flu, Placebo</arm_group_label>
    <arm_group_label>Arm 6: Flu, Pneumovax, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection with sterile saline (placebo).</description>
    <arm_group_label>Placebo, Flu, Pneumovax</arm_group_label>
    <arm_group_label>Arm 2: Placebo, Pneumovax, Flu</arm_group_label>
    <arm_group_label>Arm 3: Flu, Placebo, Pneumovax</arm_group_label>
    <arm_group_label>Arm 4: Pneumovax, Placebo, Flu</arm_group_label>
    <arm_group_label>Arm 5: Pneumovax, Flu, Placebo</arm_group_label>
    <arm_group_label>Arm 6: Flu, Pneumovax, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection (HIV antibody or viral load positive).

          -  Capable of signing written informed consent.

          -  Men and women between 18 and 50 years of age.

          -  Read and comprehend English.

          -  CD4 count at enrollment &gt;350 cells/ml and nadir &gt;200 cells/ml.

          -  Recent vaccination history (previous year flu vaccination and pneumovax at least 4
             weeks prior to screening visit) and antibody levels consistent with previous
             vaccination with both influenza and pneumococcus.

          -  Must be on non-nucleoside reverse transcriptase or integrate inhibitor base ART.

        Exclusion Criteria:

          -  Uncontrolled psychiatric condition.

          -  Under the influence of drug(s) or alcohol at time of screening.

          -  Any condition that, in the opinion of the investigator, would limit follow-up and
             adequate consent.

          -  History of allergic reactions to any of the proposed vaccines or egg allergy.

          -  History of Gullian Barre syndrome.

          -  Receiving immunosuppressive medications.

          -  Pregnancy or lactation.

          -  Receiving an ART regiment that contains a protease inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Kunkel, RN</last_name>
    <phone>619-543-3094</phone>
    <email>jkunkel@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pieter Baker, MPH</last_name>
    <phone>619-543-2759</phone>
    <email>pabaker@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center (AVRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Kunkel, RN</last_name>
      <phone>619-543-3094</phone>
      <email>jkunkel@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pieter Baker, MPH</last_name>
      <phone>619-543-2759</phone>
      <email>pabaker@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Little, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Gianella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>David Smith</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Immune Stimulation</keyword>
  <keyword>HIV Reservoir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

